Drug intelligence / Profile preview

Dermolaval

Development stage: Unknown
Lead developer: Harras Pharma Curarina
Administration: Topical

Overview

Dermolaval is a medical cosmetic shower gel and shampoo developed by Harras Pharma Curarina Arzneimittel GmbH for the daily cleansing and care of skin and scalp affected by dermatological conditions. Its primary active ingredient is Propolis Special Extract GH 2002, a purified form of bee propolis processed to remove allergenic waxes and resins. The formulation also includes burdock root extract (*Arctium lappa*) and hydrolyzed elastin. It is specifically indicated for patients with acne, seborrhea, psoriasis, dandruff, and sensitive or irritated skin. As a soap-free, pH-balanced (5.5) product, it aims to reduce inflammation, itching, and redness while maintaining the skin's natural protective barrier.

Brand names: Dermolaval
Other names: Dermolaval Duschgel und Shampoo

Beyond the preview

Go deeper on Dermolaval.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dermolaval.

Explore the full profile